Sir John Rogerson’s Quay
353 1 817 0370
Full-time employees: 295
|Mr. Mauro Severino Ajani||Founder & Exec. Chairman||427.88k||N/A||1955|
|Mr. Alessandro E. Della Cha LL.M||CEO & Exec. Director||1.12M||N/A||1963|
|Mr. Ngo Dinh Nhan||Pres of Cosmo Intelligent Medical Devices||N/A||N/A||1979|
|Mr. Giulio Evangelisti||SVP of Manufacturing, Service and Security (IMD)||N/A||N/A||1970|
|Mr. Niall Donnelly||Chief Financial Officer||N/A||N/A||1972|
|Mr. Marco Lecchi||Chief Operating Officer||N/A||N/A||1964|
|Mr. Davide Malavasi||Qualified Person & Technical Director||N/A||N/A||1973|
|Mr. Luigi Longo||Chief Scientific Officer||N/A||N/A||1979|
|Ms. Hazel Winchester||Head of Investor Relations||N/A||N/A||1971|
|Mr. Biagio Vigano||Chief People Officer||N/A||N/A||1974|
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Cosmo Pharmaceuticals N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.